journal
MENU ▼
Read by QxMD icon Read
search

CNS Drugs

journal
https://www.readbyqxmd.com/read/29858836/correction-to-long-acting-injectable-second-generation-antipsychotics-an-update-and-comparison-between-agents
#1
Michael W Jann, Scott R Penzak
1. In Page 244, under General Pharmacokinetic Principles, Column 1-the following sentence should come after reference 21.
June 2, 2018: CNS Drugs
https://www.readbyqxmd.com/read/29808469/md1003-high-dose-pharmaceutical-grade-biotin-for-the-treatment-of-chronic-visual-loss-related-to-optic-neuritis-in-multiple-sclerosis-a-randomized-double-blind-placebo-controlled-study
#2
Ayman Tourbah, Olivier Gout, Alain Vighetto, Véronique Deburghgraeve, Jean Pelletier, Caroline Papeix, Christine Lebrun-Frenay, Pierre Labauge, David Brassat, Ahmed Toosy, David-Axel Laplaud, Olivier Outteryck, Thibault Moreau, Marc Debouverie, Pierre Clavelou, Olivier Heinzlef, Jérôme De Sèze, Gilles Defer, Frédéric Sedel, Carl Arndt
BACKGROUND: Chronic visual loss is a disabling feature in patients with multiple sclerosis (MS). It was recently shown that MD1003 (high-dose pharmaceutical-grade biotin or hdPB) may improve disability in patients with progressive MS. OBJECTIVE: The aim of this study was to evaluate whether MD1003 improves vision compared with placebo in MS patients with chronic visual loss. METHODS: The MS-ON was a 6-month, randomized, double-blind, placebo-controlled study with a 6-month open-label extension phase...
May 28, 2018: CNS Drugs
https://www.readbyqxmd.com/read/29799091/systemic-therapy-of-lung-cancer-cns-metastases-using-molecularly-targeted-agents-and-immune-checkpoint-inhibitors
#3
REVIEW
Grainne M O'Kane, Natasha B Leighl
Central nervous system (CNS) metastases most commonly arise from lung cancer, with the majority of patients affected during their disease course. The prognosis for patients with untreated brain metastases is poor, with surgical resection and/or radiotherapy as classic therapeutic options. However, the value of systemic therapy in the management of CNS metastases from lung cancer is growing. Novel targeted agents for the treatment of non-small cell lung cancer (NSCLC) have demonstrated activity in treating patients with CNS involvement, and are potential alternatives to radiation and surgery...
May 24, 2018: CNS Drugs
https://www.readbyqxmd.com/read/29796977/prescription-of-zolpidem-and-the-risk-of-fatal-motor-vehicle-collisions-a-population-based-case-crossover-study-from-south-korea
#4
Bo Ram Yang, Ye-Jee Kim, Mi-Sook Kim, Sun-Young Jung, Nam-Kyong Choi, Byungkwan Hwang, Byung-Joo Park, Joongyub Lee
BACKGROUND: Zolpidem is one of the most frequently used hypnotics worldwide, but associations with serious adverse effects such as motor vehicle collisions have been reported. OBJECTIVE: The objective of this study was to evaluate the association of fatal motor vehicle collisions with a prescription for zolpidem, considering the context of the motor vehicle collisions. METHODS: We conducted a case-crossover study, where each case served as its own control, by linking data about fatal motor vehicle collisions from the Korean Road Traffic Authority between 2010 and 2014 with national health insurance data...
May 23, 2018: CNS Drugs
https://www.readbyqxmd.com/read/29790103/growth-and-puberty-in-a-2-year-open-label-study-of-lisdexamfetamine-dimesylate-in-children-and-adolescents-with-attention-deficit-hyperactivity-disorder
#5
Tobias Banaschewski, Mats Johnson, Peter Nagy, Isabel Hernández Otero, César A Soutullo, Brian Yan, Alessandro Zuddas, David R Coghill
BACKGROUND: Stimulant medications for the treatment of attention-deficit/hyperactivity disorder have a history of safe and effective use; however, concerns exist that they may adversely affect growth trajectories in children and adolescents. OBJECTIVE: The objective of this study was to evaluate the longer-term effects of lisdexamfetamine dimesylate on weight, height, body mass index and pubertal development in children and adolescents with attention-deficit/hyperactivity disorder...
May 23, 2018: CNS Drugs
https://www.readbyqxmd.com/read/29785508/lacosamide-a-review-in-focal-onset-seizures-in-patients-with-epilepsy
#6
Sheridan M Hoy
Lacosamide (Vimpat® ) is a functionalized amino acid (available orally and intravenously) approved in the EU and the USA for use as monotherapy and adjunctive therapy for the treatment of focal-onset seizures in adults, adolescents and children aged ≥ 4 years with epilepsy. In adults and adolescents (aged ≥ 16 years), oral lacosamide as adjunctive therapy to other antiepileptic drugs was generally effective in reducing seizure frequency during short-term (up to 18 weeks) treatment, with efficacy sustained over the longer-term (up to 8 years)...
May 21, 2018: CNS Drugs
https://www.readbyqxmd.com/read/29767815/the-effect-of-glatiramer-acetate-on-retinal-nerve-fiber-layer-thickness-in-patients-with-relapsing-remitting-multiple-sclerosis-a-longitudinal-optical-coherence-tomography-study
#7
Robert Zivadinov, Eleonora Tavazzi, Jesper Hagemeier, Ellen Carl, David Hojnacki, Channa Kolb, Bianca Weinstock-Guttman
BACKGROUND: Optical coherence tomography (OCT) is a technique that allows for the assessment of retinal nerve fiber layer thickness (RNFLT) and total macular volume (TMV), which reflect neuroaxonal integrity within the retina. As such it has been used in multiple sclerosis (MS) to study neurodegeneration. Glatiramer acetate (GA) is a widely used treatment for MS, which is suggested to have a possible neuroprotective role. OBJECTIVE: The aim of this study was to assess RFNLT and TMV changes in relapsing-remitting MS (RRMS) patients who started treatment with GA and were followed for a 24-month period...
May 16, 2018: CNS Drugs
https://www.readbyqxmd.com/read/29766402/correction-to-gadolinium-based-contrast-agent-related-toxicities
#8
Luca Pasquini, Antonio Napolitano, Emiliano Visconti, Daniela Longo, Andrea Romano, Paolo Tomà, Maria Camilla Rossi Espagnet
The name of the last author (as shown in the author listing on page 229) was incorrectly tagged during the journal production process, and so appears incorrectly in the PubMed record. The name should be indexed in PubMed as.
May 15, 2018: CNS Drugs
https://www.readbyqxmd.com/read/29761344/beyond-the-magic-bullet-current-progress-of-therapeutic-vaccination-in-multiple-sclerosis
#9
Barbara Willekens, Nathalie Cools
Multiple sclerosis (MS) is a chronic immune-mediated disease of the central nervous system (CNS) characterized by neuroinflammation, neurodegeneration and impaired repair mechanisms that lead to neurological disability. The crux of MS is the patient's own immune cells attacking self-antigens in the CNS, namely the myelin sheath that protects nerve cells of the brain and spinal cord. Restoring antigen-specific tolerance via therapeutic vaccination is an innovative and exciting approach in MS therapy. Indeed, leveraging the body's attempt to prevent autoimmunity, i...
May 14, 2018: CNS Drugs
https://www.readbyqxmd.com/read/29761343/role-of-exogenous-progesterone-in-the-treatment-of-men-and-women-with-substance-use-disorders-a-narrative-review
#10
REVIEW
MacKenzie R Peltier, Mehmet Sofuoglu
Substance use disorders (SUDs) remain problematic as many individuals are untreated or do not benefit from the currently available interventions. Thus, there is an urgent need to develop novel pharmacological interventions to treat SUDs. Evidence suggests that the female sex hormone, progesterone, attenuates the craving for and the euphoric effects of drugs of abuse. Research to date has demonstrated that progesterone may modulate responses to drugs of abuse and may have utility as a novel treatment for SUDs...
May 14, 2018: CNS Drugs
https://www.readbyqxmd.com/read/29752625/polypharmacy-among-headache-patients-a-cross-sectional-study
#11
Anna Ferrari, Carlo Baraldi, Manuela Licata, Cecilia Rustichelli
BACKGROUND: Polypharmacy can appropriately treat multiple chronic conditions, but it can also increase potential harm. Polypharmacy information for primary headaches is minimal, despite drugs being the main tools to manage headaches. OBJECTIVE: The aim was to evaluate the prevalence, characteristics and risk factors of polypharmacy in patients with primary headaches and examine whether these variables differ between episodic and chronic headache patients. METHODS: We analysed polypharmacy (simultaneous use of five or more medications), medication type, comorbidity, and risk factors in 300 patients (mean age 42...
May 11, 2018: CNS Drugs
https://www.readbyqxmd.com/read/29736745/activation-of-the-cannabinoid-type-2-receptor-by-a-novel-indazole-derivative-normalizes-the-survival-pattern-of-lymphoblasts-from-patients-with-late-onset-alzheimer-s-disease
#12
Patricia Del Cerro, Carolina Alquézar, Fernando Bartolomé, Pedro González-Naranjo, Concepción Pérez, Eva Carro, Juan A Páez, Nuria E Campillo, Ángeles Martín-Requero
BACKGROUND: Alzheimer's disease is a multifactorial disorder for which there is no disease-modifying treatment yet. CB2 receptors have emerged as a promising therapeutic target for Alzheimer's disease because they are expressed in neuronal and glial cells and their activation has no psychoactive effects. OBJECTIVE: The aim of this study was to investigate whether activation of the CB2 receptor would restore the aberrant enhanced proliferative activity characteristic of immortalized lymphocytes from patients with late-onset Alzheimer's disease...
May 7, 2018: CNS Drugs
https://www.readbyqxmd.com/read/29736744/antidepressant-efficacy-and-tolerability-of-ketamine-and-esketamine-a-critical-review
#13
REVIEW
P Molero, J A Ramos-Quiroga, R Martin-Santos, E Calvo-Sánchez, L Gutiérrez-Rojas, J J Meana
Ketamine and its enantiomer S-ketamine (esketamine) are promising candidates to produce a rapid-onset antidepressant effect in treatment-resistant depression. Ketamine causes continued blockade of the glutamate N-methyl-D-aspartate (NMDA) receptor, though this might not primarily mediate the antidepressant effect. Alternative hypotheses include selectivity for the NMDA receptor subtype containing the NMDA receptor subunit 2B (NR2B), inhibition of the phosphorylation of the eukaryotic elongation factor 2 (eEF2) kinase, increased expression of brain-derived neurotrophic factor (BDNF) and tropomyosin receptor kinase B (TrKB), and activation of the mammalian target of rapamycin (mTOR) signaling pathway, alongside other independent actions attributed to the ketamine metabolism to R-hydroxynorketamine (R-HNK)...
May 7, 2018: CNS Drugs
https://www.readbyqxmd.com/read/29796978/correction-to-efficacy-and-safety-of-the-newer-multiple-sclerosis-drugs-approved-since-2010
#14
Simon Faissner, Ralf Gold
An error was subsequently identified in the article, and the following correction should be noted.
May 2018: CNS Drugs
https://www.readbyqxmd.com/read/29651711/baclofen-to-prevent-relapse-in-gamma-hydroxybutyrate-ghb-dependent-patients-a-multicentre-open-label-non-randomized-controlled-trial
#15
Harmen Beurmanjer, Rama M Kamal, Cor A J de Jong, Boukje A G Dijkstra, Arnt F A Schellekens
BACKGROUND: Gamma-hydroxybutyrate (GHB) dependence is associated with a severe, potentially lethal, withdrawal syndrome and relapse rates as high as 60% within 3 months of detoxification. Baclofen has been shown to decrease self-administration of GHB in mice and reduce relapse in a case series of GHB-dependent patients. Controlled studies on the effectiveness of baclofen to prevent relapse in GHB-dependent patients are lacking. AIM: The aim of this study was to assess effectiveness of baclofen in preventing relapse in GHB-dependent patients...
May 2018: CNS Drugs
https://www.readbyqxmd.com/read/29637529/nd0701-a-novel-formulation-of-apomorphine-for-subcutaneous-infusion-in-comparison-to-a-commercial-apomorphine-formulation-28-day-pharmacokinetic-study-in-minipigs-and-a-phase-i-study-in-healthy-volunteers-to-assess-the-safety-tolerability-pharmacokinetics-and
#16
Yuval Ramot, Abraham Nyska, Liat Adar, Cecile Durlach, Danny Fishelovitch, Giuseppe Sacco, Rosa Anna Manno, Sheila Oren, Itay Perlstein, Oron Yacobi-Zeevi
BACKGROUND: Subcutaneous apomorphine is used for the treatment of Parkinson's disease (PD); however, infusion site reactions are a common adverse event (AE), which can lead to treatment discontinuation. Apomorphine formulations that are more tolerable and convenient for use are needed. OBJECTIVE: Our aim was to compare the toxicity and bioavailability of ND0701, a new concentrated formulation of apomorphine free base, with one of the commercially available apomorphine HCl formulations (APO-go® , Britannia Pharmaceuticals Ltd)...
May 2018: CNS Drugs
https://www.readbyqxmd.com/read/29637530/the-safety-of-second-generation-antipsychotics-during-pregnancy-a-clinically-focused-review
#17
REVIEW
Per Damkier, Poul Videbech
The issue of antipsychotic treatment during pregnancy is subject to substantial uncertainty and some controversy among healthcare providers, specifically pertaining to second-generation antipsychotics (SGAs) that are subject to a large gap in safety data during pregnancy compared with antidepressants. The amount of safety data for the use of SGAs during pregnancy is rapidly increasing, thus constantly changing the level of evidence. We performed a clinically focused review on the safety of SGA during pregnancy...
April 2018: CNS Drugs
https://www.readbyqxmd.com/read/29637528/author-correction-to-pooled-analyses-of-phase-iii-studies-of-ads-5102-amantadine-extended-release-capsules-for-dyskinesia-in-parkinson-s-disease
#18
Lawrence W Elmer, Jorge L Juncos, Carlos Singer, Daniel D Truong, Susan R Criswell, Sotirios Parashos, Larissa Felt, Reed Johnson, Rajiv Patni
An Online First version of this article was made available online at http://link.springer.com/journal/40263/onlineFirst/page/1 on 12 March 2018. An error was subsequently identified in the article, and the following correction should be noted.
April 2018: CNS Drugs
https://www.readbyqxmd.com/read/29623639/pharmacogenetics-of-opioid-use-disorder-treatment
#19
Richard C Crist, Toni-Kim Clarke, Wade H Berrettini
Opioid use disorder (OUD) is a significant health problem in the United States and many other countries. A combination of issues, most notably increased prescription of opioid analgesics, has resulted in climbing rates of opioid abuse and overdose over the last decade. This ongoing epidemic has produced a growing population of patients requiring treatment for OUD. Medications such as methadone and buprenorphine have well documented success rates in treating the disorder compared with placebo. However, significant percentages of the population still fail to maintain abstinence or reduce illicit opioid use while using such medications...
April 2018: CNS Drugs
https://www.readbyqxmd.com/read/29619760/effect-of-statin-intensity-on-the-risk-of-epilepsy-after-ischaemic-stroke-real-world-evidence-from-population-based-health-claims
#20
Fang-Ju Lin, Hung-Wei Lin, Yunn-Fang Ho
BACKGROUND: Statins possess neuroprotective effects. However, real-world evidence supporting their utility in post-stroke epilepsy (PSE) prevention is limited. OBJECTIVE: The association between statin use, including timing of prescribing (pre-stroke vs post-stroke), type (lipophilicity, intensity of therapy) and dose intensity, and risk of developing PSE were investigated by studying Taiwanese health claims (2003-2013). METHODS: Patients with new-onset ischaemic stroke were identified...
April 2018: CNS Drugs
journal
journal
31926
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"